

IAS 2015 OFFICIAL PRESS CONFERENCE SCHEDULE

All press conferences will be held in the Media Centre, located in rooms W220-222 on the West Level 2 of the Vancouver Convention Centre.

Embargo Policy: The embargo on the following abstracts lifts at the start time of the press conference in which the oral abstract is featured or at the start time of the scientific session in which the abstract is presented – whichever is earlier.

Remote Access: All official IAS 2015 press conferences will be livestreamed. You may access the briefings live here.

Official press conferences will be made accessible to reporters outside the conference venue; detailed access information will be provided prior to the start of the press conference.

SUNDAY, 19 JULY 2015

Official IAS 2015 Opening Press Conference

TIME: 17.30-18.30 (PDT)

TOPICS:

- Overview of newsworthy data and other announcements at the conference
- Preview of select plenary addresses
- Discussion of global HIV treatment targets
- 30/30 Project, founded by musician and director Ryan Lewis (known for his collaborations with Macklemore) and his mother, Julie Lewis (a 30-year HIV survivor)

PRESS CONFERENCE CHAIR:

 Chris Beyrer, MD, Johns Hopkins University – IAS 2015 International Chair & International AIDS Society President

SPEAKERS:

- Chris Beyrer, MD
- Julio Montaner, MD, IAS 2015 Local Co Chair; Director, British Columbia Centre for Excellence in HIV/AIDS
- Nora Volkow, MD, Director, U.S. National Institute on Drug Abuse
- Michel Sidibé, Executive Director, UNAIDS
- Amb. Deborah Birx, MD, U.S. Global AIDS Coordinator
- Ryan & Julie Lewis, Founders, 30/30 Project

MONDAY, 20 JULY 2015

Official IAS 2015 Press Conference: Earlier Initiation of HIV Treatment, Treatment as Prevention (TasP) & Non-Daily PrEP Use

TIME: 9.15-10.15 (PDT)

TOPICS:

- Full results from the Strategic Timing of Antiretroviral Treatment (START) study, a trial recently stopped early based on preliminary data that clearly showed individuals with HIV have a considerably lower risk of developing AIDS or other serious illnesses if they begin ARV treatment soon after diagnosis
- Final data from HPTN 052 a landmark trial answering whether dramatic decreases in sexual transmission of HIV from individuals whose infections were suppressed through therapy were sustained over the course of the multi-year study
- Preview of updated WHO ARV guidelines, including guidance on pre-exposure prophylaxis (PrEP)
- Findings from the HPTN 067 ADAPT trial examining adherence and other factors related to the
 use of non-daily (or intermittent) PrEP in Cape Town, Bangkok and Harlem; findings will have
 significant implications for PrEP rollout worldwide and for the use among women and men who
 have sex with men (MSM)

PRESS CONFERENCE CHAIR:

 Julio Montaner, MD, IAS 2015 Local Co Chair; Director, British Columbia Centre for Excellence in HIV/AIDS

SPEAKERS:

- Jens Lundgren, MD (START), University of Copenhagen
- Myron Cohen, MD (HPTN 052), University of North Carolina School of Medicine
- Gottfried Hirnschall, MD (ARV Guidelines), WHO
- Bob Grant, MD (ADAPT), University of California, San Francisco
- Dazon Dixon Diallo (Community Perspective), SisterLove, Inc., Atlanta

Official IAS 2015 Press Conference: PrEP Implementation

TIME: 16.30-17.30 (PDT)

TOPICS:

- First data from the US PrEP Demo Project exploring PrEP adherence, sexual behaviors and HIV/STI incidence among MSM and transgender women in Miami, San Francisco and Washington, DC
- Results from PrEP Brasil,the first PrEP demonstration project for MSM and transgender women in a middle-income country
- Data from ATN 110 examining PrEP uptake and adherence among young MSM in 12 U.S. cities
- Final results from TDF2 OLE PrEP study, the U.S. Centers for Disease Control & Prevention's 12-month open-label extension trial assessing PrEP use among young heterosexual adults in Botswana
- Overview of a special PrEP-themed issue of the Journal of the International AIDS Society (JIAS)

PRESS CONFERENCE CHAIR:

 Chris Beyrer, MD, IAS 2015 International Chair; President, International AIDS Society; Professor, The Johns Hopkins University

IAS 2015 Official Press Conference Schedule – Subject to Change

SPEAKERS:

- Albert Liu, MD (U.S. PrEP Demo), San Francisco Department of Public Health
- Beatriz Grinsztejn, MD (PrEP Brasil), Instituto Pesq Clinica Evandro Chagas, Rio de Janeiro
- Sybil Hosek, PhD (ATN 110), Stroger Hospital, Chicago
- Faith Henderson (TDF2 OLE), CDC
- Carlos F. Cáceres, MD (JIAS), Cayetano Heredia University, Lima

TUESDAY, 21 JULY 2015

Official IAS 2015 Press Conference: Towards an HIV Cure

TIME: 9.15-10.15 (PDT)

TOPICS:

The press briefing will reflect on where the field of HIV cure research has come in the past year and where it may be headed, and focus on key studies being presented in Vancouver, including:

- Case of a perinatally HIV-infected adolescent showing unprecedented virological remission many years after ARV discontinuation
- Convergence of research suggesting that broadly neutralizing antibodies may play a key role in developing both a vaccine and a cure for HIV
- First-time findings on Zinc Finger Nuclease genome editing describing use of long-term, multilineage engraftment of gene-edited immune cells targeting the CCR5 protein necessary for HIV cell infection

PRESS CONFERENCE CO-CHAIRS:

- Françoise Barré-Sinoussi, PhD, Institut Pasteur, Paris
- Sharon Lewin, PhD, University of Melbourne
- Steven Deeks, MD, University of California, San Francisco

SPEAKERS:

- Asier Saez-Cirion, PhD (Long-Term Remission), Institut Pasteur, Paris
- John Mascola, MD (Broadly Neutralizing Antibodies), U.S. National Institutes of Health
- Sarah Fidler, MD (Partnerships), Imperial College London
- Christopher Peterson, PhD (Zinc Finger), Fred Hutchinson Cancer Research Centre, Seattle
- Lynda Dee (Community Perspective), AIDS Action Baltimore

WEDNESDAY, 22 JULY 2015

Official IAS Press Conference: HIV-Hepatitis Co-Infection

TIME: 9.15-10.15 (PDT)

TOPICS:

• The press briefing will provide an overview of key treatment and other research presented at the conference, latest prevention approaches and expansion of global access to treatment/prevention of hepatitis B and C among people co-infected with HIV.

PRESS CONFERENCE CHAIR:

Linda-Gail Bekker, Desmund Tutu HIV Centre, Cape Town

IAS 2015 Official Press Conference Schedule - Subject to Change

SPEAKERS:

- Tracy Swan, Treatment Action Group
- Anchalee Avihingsanon, MD, Thai Red Cross AIDS Research Centre
- Marina Klein, MD, McGill University, Canada
- Jürgen Rockstroh, MD, University of Bonn, Germany